Affymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel...
Affymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel for its peginesatide treatment of anemia in dialysis patients. Cowen believes the drug can capture $250M in U.S. sales by 2016, and Raymond James suspects AFFY can take market share if it prices its drug lower than Amgen's (AMGN +1%) Epogen.
From other sites
at MarketWatch.com (Jun 3, 2013)
at CNBC.com (May 31, 2013)
at MarketWatch.com (Apr 2, 2013)
at MarketWatch.com (Mar 19, 2013)
at CNBC.com (Mar 19, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs